Once-Weekly Semaglutide in Adults with Overweight or Obesity
Семаглутид один раз в неделю у взрослых с избыточной массой тела или ожирением
2021-02-10
SCID: 54.1/y86wscez
Discuss with AI
double-blind triallifestyle interventionobesityonce-weekly semaglutideweight loss
Figures from the paper
Abstract (AI)
BACKGROUND: Obesity is a global health challenge with few pharmacologic options. Whether adults with obesity can achieve weight loss with once-weekly semaglutide at a dose of 2.4 mg as an adjunct to lifestyle intervention has not been confirmed. METHODS: In this double-blind trial, we enrolled 1961 adults with a body-mass index (the weight in kilograms divided by the square of the height in meters) of 30 or greater (≥27 in persons with ≥1 weight-related coexisting condition), who did not have diabetes, and randomly assigned them, in a 2:1 ratio, to 68 weeks of treatment with once-weekly subcutaneous semaglutide (at a dose of 2.4 mg) or placebo, plus lifestyle intervention. The coprimary end points were the percentage change in body weight and weight reduction of at least 5%. The primary estimand (a precise description of the treatment effect reflecting the objective of the clinical trial) assessed effects regardless of treatment discontinuation or rescue interventions. RESULTS: The mean change in body weight from baseline to week 68 was -14.9% in the semaglutide group as compared with -2.4% with placebo, for an estimated treatment difference of -12.4 percentage points (95% confidence interval [CI], -13.4 to -11.5; P<0.001). More participants in the semaglutide group than in the placebo group achieved weight reductions of 5% or more (1047 participants [86.4%] vs. 182 [31.5%]), 10% or more (838 [69.1%] vs. 69 [12.0%]), and 15% or more (612 [50.5%] vs. 28 [4.9%]) at week 68 (P<0.001 for all three comparisons of odds). The change in body weight from baseline to week 68 was -15.3 kg in the semaglutide group as compared with -2.6 kg in the placebo group (estimated treatment difference, -12.7 kg; 95% CI, -13.7 to -11.7). Participants who received semaglutide had a greater improvement with respect to cardiometabolic risk factors and a greater increase in participant-reported physical functioning from baseline than those who received placebo. Nausea and diarrhea were the most common adverse events with semaglutide; they were typically transient and mild-to-moderate in severity and subsided with time. More participants in the semaglutide group than in the placebo group discontinued treatment owing to gastrointestinal events (59 [4.5%] vs. 5 [0.8%]). CONCLUSIONS: In participants with overweight or obesity, 2.4 mg of semaglutide once weekly plus lifestyle intervention was associated with sustained, clinically relevant reduction in body weight. (Funded by Novo Nordisk; STEP 1 ClinicalTrials.gov number, NCT03548935).
Key Findings
1
In a 68-week double-blind trial of adults without diabetes and with overweight or obesity, once-weekly semaglutide 2.4 mg plus lifestyle intervention reduced body weight by 14.9% versus 2.4% with placebo.
2
Mean absolute weight loss was 15.3 kg with semaglutide versus 2.6 kg with placebo, an estimated treatment difference of -12.7 kg.
3
Semaglutide produced substantially more participants achieving at least 5%, 10%, and 15% weight loss: 86.4%, 69.1%, and 50.5%, respectively, versus 31.5%, 12.0%, and 4.9% with placebo.
4
Semaglutide was associated with greater improvements in cardiometabolic risk factors and participant-reported physical functioning than placebo; nausea and diarrhea were reported adverse effects.
5
The estimated treatment difference in percentage body-weight change was -12.4 percentage points (95% CI, -13.4 to -11.5; P<0.001).
Research Object
Adults with overweight or obesity receiving once-weekly subcutaneous semaglutide 2.4 mg plus lifestyle intervention
Research Subject
Weight-loss efficacy and effects on cardiometabolic risk factors and physical functioning over 68 weeks
Publication Details
Publication Date
2021-02-10
Journal
Publisher
ISSN
Cited by
5205
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai2
Cited by20
Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association2023
Tirzepatide Once Weekly for the Treatment of Obesity2022
2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association2024
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)2022
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity2023
Obesity and Cancer: A Current Overview of Epidemiology, Pathogenesis, Outcomes, and Management2023
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity2025
Obesity Management in Adults2023
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society–USA Panel2022
Tirzepatide for Obesity Treatment and Diabetes Prevention2024
Changes in lean body mass with glucagon‐like peptide ‐1‐based therapies and mitigation strategies2024
The evolving story of incretins ( GIP and GLP ‐1) in metabolic and cardiovascular disease: A pathophysiological update2021
2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines2025
Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity2022
2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines2025
Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks2024
Glucagon-Like Peptide 1 Receptor Agonists and Mental Health2025
Evolving Paradigms of Recombinant Protein Production in Pharmaceutical Industry: A Rigorous Review2024
The Effects of GLP-1 Agonists on Musculoskeletal Health and Orthopedic Care2025
Cardiometabolic comorbidities and complications of obesity and chronic kidney disease (CKD)2024